Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States.
Bogart M, Bengtson LGS, Johnson MG, Bunner SH, Gronroos NN, DiRocco KK. Bogart M, et al. Among authors: bengtson lgs. Int J Chron Obstruct Pulmon Dis. 2024 Jan 11;19:97-110. doi: 10.2147/COPD.S424497. eCollection 2024. Int J Chron Obstruct Pulmon Dis. 2024. PMID: 38226396 Free PMC article.
Phase Ib trial of inhaled iloprost for the prevention of lung cancer with predictive and response biomarker assessment.
Miller YE, Ghosh M, Merrick DT, Kubala B, Szabo E, Bengtson L, Kocherginsky M, Helenowski IB, Benante K, Schering T, Kim J, Kim H, Ha D, Bergan RC, Khan SA, Keith RL. Miller YE, et al. Among authors: bengtson l. Front Oncol. 2023 Aug 30;13:1204726. doi: 10.3389/fonc.2023.1204726. eCollection 2023. Front Oncol. 2023. PMID: 37711198 Free PMC article.
Real-world primary nonadherence to antiobesity medications.
Kan H, Bae JP, Dunn JP, Buysman EK, Gronroos NN, Swindle JP, Bengtson LGS, Ahmad N. Kan H, et al. Among authors: bengtson lgs. J Manag Care Spec Pharm. 2023 Oct;29(10):1099-1108. doi: 10.18553/jmcp.2023.23083. Epub 2023 Aug 18. J Manag Care Spec Pharm. 2023. PMID: 37594848 Free PMC article.
Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History.
Sethi S, Clark B, Bengtson LGS, Buysman EK, Palli S, Sargent A, Shaikh A, Ferguson GT. Sethi S, et al. Among authors: bengtson lgs. Int J Chron Obstruct Pulmon Dis. 2023 Apr 19;18:625-641. doi: 10.2147/COPD.S386962. eCollection 2023. Int J Chron Obstruct Pulmon Dis. 2023. PMID: 37155497 Free PMC article.
Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
Sethi S, Palli SR, Bengtson LGS, Buysman EK, Clark B, Sargent A, Shaikh A, Ferguson GT. Sethi S, et al. Among authors: bengtson lgs. J Manag Care Spec Pharm. 2023 Jul;29(7):791-806. doi: 10.18553/jmcp.2023.22373. Epub 2023 May 3. J Manag Care Spec Pharm. 2023. PMID: 37133429 Free PMC article.
68 results